---
notetoolbar: Study
tags:
  - ISascpi
---

# PRINCIPLES OF IMMUNOLOGY

## Immune System Physiology
?
![[Pasted image 20240505144826.png]]
> [!important] 4 types of acquired immunity
> - Natural
> 	- Active (infection)
> 	- Passive (transplacental IgG transfer)
> - Artificial
> 	- Active (Vaccination)
> 	- Passive (HbIg)

## Acute Phase Reactants
?
> [!NOTE]
> humoral component of NATURAL immunity
> majority are produced in the LIVER, driven by IL-<mark class="red">6</mark>

- **Binds receptors** on phagocytic cells<br>- Capable of **Opsonization**, **Agglutination**, **Precipitation** and **Complement Activation**<br>- Binding is **NON-SPECIFIC** and **CALCIUM dependent**<br>- Increases rapidly with levels up to **1000x higher**, **peaking at 48 hours** (MOST SENSITIVE)::<mark class="red">C-RP</mark>
- Activates **Monocytes** and **Macrophages** producing inflammatory molecules<br>- Produce in the **LIVER**, transported by HDL to the site of infection::<mark class="red">Serum Amyloid A</mark>
Functions in **Opsonization**, **Chemotaxis** and **Lysis of Cells**::<mark class="red">Complement</mark>
Limits the harmful effects of the immune system by **INHIBITING proteases** (elastase) released from leukocytes and **regulating expression of proinflammatory cytokines**<br><br>deficiency results to: **Pulmonary emphysema**, **Juvenile cirrhosis**::<mark class="red">a-1 antitrypsin</mark>
**Antioxidant**, binds IRreversibly to free hemoglobin::<mark class="red">Haptoglobin</mark>
Promotes **clot formation**::<mark class="red">Fibrinogen</mark>
Principle **copper-transporting protein** in plasma::<mark class="red">Ceruloplasmin</mark>

[!NOTE] Negative APRs (decreased when there is inflammation)
?
- <mark class="red">Albumin</mark>
- <mark class="red">Prealbumin/Transthyretin</mark>
- <mark class="red">Transferrin</mark>

## Phagocytosis
?
![[IS (ASCPi)#^0ighf5]]


- Made possible thru **TLRs** found on surface of phagocytes::<mark class="red">Initiation</mark>
- Migration of phagocytes **from the blood vessels (capillaries) to injured tissue**::<mark class="red">Diapedesis</mark>
- Phagocytes move **toward or away other cells** in response to chemotaxins::<mark class="red">Chemotaxis</mark>
- **Outflowing of cytoplasm** occurs and **formation of PHAGOSOME**<br>::<mark class="red">Engulfment</mark>
- **Release of enzymes** from granules; **respiratory burst** occurs via oxidative metabolism::<mark class="red">Digestion</mark>



[!NOTE]
?
TLRs recognize <mark class="red">pathogen-associated molecular pattern (PAMP)</mark>

[!warning] Chronic Granulomatous Dss
?
- defective NADPH oxidase system
- NADPH oxidase
	- reduces oxygen to superoxide (O2 dependent P)
	- depolarizes the membrane (O2 Independent P)
- characterized by **severe recurrent infections**
- Tests for CGD
	- $ <mark class="red">Nitroblue Tetrazolium Test</mark>
		- yellow or colorless --H2O2-→ blue formazan dye
		- if oxidative burst i PRESENT = BLUE
	- $ <mark class="red">Flow Cytometric Assay</mark>
		- label (Dhydrorhodamine)
		- activator (phorbol myristate acetate) 
		- if oxidative burst is PRESENT = FLUORESCENCE ^rf18hg

## Lymphocytes
?
![[IS (ASCPi)#^i4rk48]]

### MATURATION STAGES OF LYMPHOCYTES

#### B Cell Maturation


Rearrangement of genes coding for **heavy chains** and **light chains**<br><br>Chromosome <mark class="red">14</mark> (Heavy chains); Chromosome <mark class="red">2& 22</mark> (Light chains)<br><br>CD<mark class="red">19</mark>, CD<mark class="red">45R</mark>, CD<mark class="red">43</mark>, CD<mark class="red">24</mark>, and <mark class="red">c-kit</mark>::<mark class="red">Pro-B cell</mark>
Appearance of **mu chains** (heavy chain)::<mark class="red">Pre-B cell</mark>
Appearance of **surface IgM**<br><br>IgM: pentamer (in blood), monomer (in surface of B cell)<br><br>CD<mark class="red">21</mark>, CD<mark class="red">40</mark>, <mark class="red">MHC Class II</mark><br><br>where Selection process starts::<mark class="red">Immature B cell (competent B cell)</mark>
Appearance of **surface IgM and IgD, MHC Class II**::<mark class="red">Mature B cell</mark>
Appearance of CD<mark class="red">25</mark> which serves as **receptor for IL-<mark class="red">2</mark>**::<mark class="red">Activated B cell</mark>
Production of **antibodies**<br><br>CYTOPLASMIC immunoglobulins::<mark class="red">Plasma cell (Effector B cell)</mark>

#### T Cell Maturation

Rearrangement of genes coding for **T-cell receptor**<br>(-) CD4 and CD8<br>(+) <mark class="red">CD2, CD5 and CD7</mark><br><br>CANNOT bind an antigen yet (NO CD3)::<mark class="red">Double NEGative thymocyte</mark>
(+) <mark class="red">CD3, CD4 and CD8</mark><br><br>where **Selection process** happens::<mark class="red">Double POSitive thymocyte</mark>
Either CD4 and CD8 is present::<mark class="red">Mature T cell</mark>
Appearance of **CD25** which serves as **receptor for IL-2**::<mark class="red">Activated T cell</mark>

[!NOTE] Rosette Test
?
- sheep RBCs (attach to the CD2 antigen) - CANNOT BE used in B-cells (no CD2)
- Rosette (at least 3 RBCs)
- 200 cells are counted and solve for percent forming rosettes

### LABORATORY IDENTIFICATION OF LYMPHOCYTES USING FLOW CYTOMETRY
?
- Rapid and convenient technique for **generating immunophenotypic data**
- Useful for **evaluation and prognosis of ==LEUKEMIA==, ==LYMPHOMA==, and ==IMMUNODEFICIENCY==**
- Based on **Light Scattering** derived from **suspension of particles of a flowing stream of fluid**

Detectors::- <mark class="red">Forward scatter</mark>: measures cell **size**<br>- <mark class="red">Side Light scatter</mark>: measures cell **internal complexity / granularity**<br>- <mark class="red">Fluorescent antibodies</mark>: quantifying **cell subpopulation or cell components**
Fluorophores::<mark class="red">FITC</mark>, <mark class="red">TRITC</mark>, <mark class="red">Phycoerythrin</mark>
Specimen::<mark class="red">Blood</mark> / BM (Other: body fluid <mark class="red">aspirates</mark>, <mark class="red">tissue</mark> sample)
Anticoagulant::<mark class="red">EDTA</mark> (choice for BLOOD samples; process w/in 30 mins), <mark class="red">Heparin</mark> (improve the stability of the sample up to 24 hours) , <mark class="red">Acid citrate dextrose</mark>
Requires REMOVAL OF RBCS prior to testing::- <mark class="red">Density gradient centrifugation</mark> which uses **Ficoll-Hypaque solution** (time consuming, selective loss of some cell population)<br>- <mark class="red">Plasma</mark> (top)<br>- <mark class="red">Mononuclear cells</mark> (middle)<br>- <mark class="red">RBCs, granulocytes</mark> (bottom)
ERYTHROCYTE Lysing agent (preferred method)::uses <mark class="red">ammonium chloride</mark>



## Human Leukocyte Antigen (MHC)
?
- The HLA locus is composed of **>200 genes** located at <mark class="red">short arm of chromosome 6</mark>
- HLA antigens are inherited as **HAPLOTYPE** from each parent in a **simple Mendelian inheritance pattern.**
![[IS (ASCPi)#^pthw5x]]

[!NOTE]
?
25% chance that 2 siblings will be HLA identical

[!important] Functions/Applications:
?
- Mounting **immune responses**
- Determines **histocompatibility**, **Paternity test**
- **Disease association**


### HLA Disease and Drug Hypersensitivity Associations

B27::<mark class="red">Ankylosing spondylitis</mark>
B51::<mark class="red">Behcet disease</mark>
DQ2, DQ8::<mark class="red">Celiac disease</mark>
DQ B1\*O6:O2::<mark class="red">Narcolepsy</mark>
DR B1\*O4::<mark class="red">Rheumatoid arthritis</mark>
B\*57:O1::<mark class="red">Abacavir sensitivity</mark>
B\*15:O2::<mark class="red">Carbamazepine sensitivity</mark>
DR2, DR3::<mark class="red">SLE</mark>
DR3::<mark class="red">Autoimmune Thyroid Conditions (Grave's dss, Hashimotos thyroiditis)</mark>
DR5::<mark class="red">Alopecia areata</mark>

## Immunoglobulins
?
- Glycoproteins found in the serum portion of the blood constituting approximately **20% of plasma proteins**
- All immunoglobulins are **86 to 98% <mark class="red">polypeptide</mark>** and **2 to 14% <mark class="red">carbohydrate</mark>**
- Migrates at the **gamma (γ) region** when serum is subjected to electrophoresis at **pH 8.6**
- Major humoral component of the ADAPTIVE immune response

### STRUCTURE OF IMMUNOGLOBULINS
?
> [!NOTE] Title
> ![[Pasted image 20240505162226.png]]
- Made up of basic **four-chain Polypeptide (Tetrapeptide structure)** consisting of:
	- 2 identical <mark class="red">Heavy</mark> chains (mu, gamma, alpha, epsilon, delta)
	- 2 identical <mark class="red">Light</mark> chains (kappa, lambda)
- H and L chains are held together by <mark class="red">noncovalent forces</mark> and <mark class="red">disulfide interchain bridges</mark>
	- H - H or H - L only, NO L - L (Abnormal)
- Each chain has a variable region and one or more constant region
	- Variable region (1st 110 AA)
	- Constant region
- <mark class="red">Hinge Region</mark> (located between C1 & C2; PROLINE rich - Ab flexibility)
- Receptors (<mark class="red">CH2</mark> - complement proteins; <mark class="red">CH3</mark> - phagocytes)



### IMMUNOGLOBULIN CLASSES
?
> [!NOTE]
> Monomer (valence: 2)
> Pentamer (valence: 10)
![[IS (ASCPi)#^gs9ut1]]

### Immunoglobulin Classification Based on LOCATION OF ANTIGENIC DETERMINATES
?
If Antibodies are CONSIDERED as Antigens

Different classes based on the type of **HEAVY chain**<br><br>![[Pasted image 20240514153017.png]]::<mark class="red">Isotype</mark>
**Minor variations** present in some individuals and not other<br>Formed by **CONSTANT regions** of HEAVY and LIGHT chains<br><br>![[Pasted image 20240514153045.png]]::<mark class="red">Allotype</mark>
Epitope form by the **VARIABLE regions** of HEAVY and LIGHT chains<br><br>![[Pasted image 20240514153100.png]]::<mark class="red">Idiotype</mark>
Antibody formed **against the IDIOTYPE**::<mark class="red">Antiidiotype</mark>



### ANTIBODY RESPONSE
?
![[IS (ASCPi)#^2uzpa4]]


[!NOTE] ANTIBODY FRAGMENTATION
?
- <mark class="red">IgM</mark> (break the J chain)
	- DTT (Dithiotreitol)
	- 2-ME (2-meraptoethanol)
- <mark class="red">IgG</mark> (Monomer)
	- **PEPSIN** (cleaves the Ab BELOW the hinge region)
		- 2 fragments (1 F(ab2); 1Fc)
	- **PAPAIN** (cleaves the Ab ABOVE the hinge region)
		- 3 fragments (2 Fab; 1 Fc)

## Complement
?
- Complex series of **more than 30 soluble and cell bound proteins** that interact in a very specific way to mediate and enhance host defense mechanisms against foreign cells.
- <mark class="red">Heat labile</mark> substance present in normal nonimmune serum
- Most plasma complement proteins are **synthesized in the ==LIVER==** EXCEPT:
	1. <mark class="red">C1 components</mark>: produced by **intestinal epithelial cells**
	2. <mark class="red">Factor D</mark>: made in **adipose** tissue
- Most of these proteins are **INactive precursors**, or <mark class="red">zymogens</mark>, which are converted to active enzymes in a very precise order.

Pathways
?
![[IS (ASCPi)#^a0clfy]]

[!NOTE]
?
- Recognition (C1 components)
	- C1q (recognition component)
- Activation (cleaving of C4, C2, C3 into "a" and "b" components)
- MAC (initiated by C5)
	- C5b6789 (membrane attack complex; for cellular lysis)
``` mermaid
graph LR
A(Recognition)
B(Activation)
C(MAC)

A --> B --> C
```

[!NOTE] Other products of Complement activators
?
- Opsonins (C3b)
- Chemotaxin (C5a)
- Anaphylatoxin (C5a, C4a, C3a)

# ANTIGEN-ANTIBODY INTERACTIONS

Forces that allow antigen-antibody binding are non-covalent bonds: <mark class="red">electrostatic attraction</mark>, <mark class="red">hydrogen bonding</mark>, <mark class="red">hydrophobic interaction</mark> and<mark class="red"> van der Waals forces.</mark>
?
Affinity, Avidity

the **INITIAL force of attraction** or strength of the binding between a single combining site of an antibody and an epitope of an antigen::<mark class="red">Affinity</mark>
the **SUM total of all the forces** or overall strength of attachment of an antibody to an antigen::<mark class="red">Avidity</mark>


## ZONE OF EQUIVALENCE
?
- Occurs when the number of **multivalent sites of antigen and antibody are approximately EQUAL**
- **Optimum <mark class="red">precipitation</mark> and <mark class="red">agglutination</mark>** occur
- Failure to achieve the zone of equivalence may be caused by the following: (F NEGative reaction)
![[IS (ASCPi)#^jh25zg]]



## PRECIPITATION VS AGGLUTINATION


Binding of <mark class="red">antibodies + soluble antigens</mark> resulting in **INsoluble complexes**::<mark class="red">PRECIPITATION</mark>
Binding of <mark class="red">antibodies + particulate antigens</mark> forming **cellular aggregates**::<mark class="red">AGGLUTINATION</mark>


### Precipitation in a FLUID MEDIUM

- A measure of the **turbidity or cloudiness of a solution**<br>- A detection device is placed in **DIRECT LINE with an incident light**, measures the reduction in light intensity caused by reflection, absorption or scatter.<br>- The **lower the light intensity, the higher the concentration of complexes**::<mark class="red">TURBIDI</mark>METRY
- Measures the amount of light that is **SCATTERED at a particular ANGLE** from the incident beam as it passes through a suspension<br>- **MORE SENSITIVE** than turbidimetry (used also to measure Macromolecules: Proteins)<br>- Can be used to detect **either Antigen or Antibody**::<mark class="red">NEPHELO</mark>METRY


### Precipitation by PASSIVE IMMUNODIFFUSION
?
![[IS (ASCPi)#^obyo97]]


Uses a **tube** or **column**<br>(+) Result: <mark class="red">Precipitin band</mark><br>Ab – incorporated WITH the agar gel<br>Ag (diffusing) – layered at the TOP of agar gel<br><br>aka: <mark class="red">Oudin's technique</mark>::<mark class="red">SINGLE Diffusion in ONE Dimension</mark>
Uses a **tube** or **column**<br>(+) Result: <mark class="red">Precipitin band</mark><br>Ab (diffusing) – incorporated WITH the agar gel<br>Ag (diffusing) – layered at the TOP of agar gel<br><mark class="red">Intervening column</mark> - **plain agar** is in between (low concentration)<br><br>aka: <mark class="red">Oakley-Fulthorpe Technique</mark>::<mark class="red">DOUBLE Diffusion in ONE Dimension</mark>
- Uses a <mark class="red">flat surface</mark> – **Petri Dish** or **slide** for precipitation reaction<br>- (+) Result: <mark class="red">Precipitin ring</mark><br><br>- Ab – incorporated WITH the agar gel<br>- Ag – added to PRE-CUT WELLS<br>::<mark class="red">SINGLE Diffusion in TWO Dimensions</mark>
- Antigen is allowed to **diffuse COMPLETELY**<br>- IgG = <mark class="red">24 hours</mark> / IgM = <mark class="red">50-72 hours</mark><br><br>Interpretation: <mark class="red">d^2 = Ag concentration</mark>::<mark class="red">Mancini/Endpoint</mark> Method
- Antigen is **NOT ALLOWED to diffuse** completely <br>- Measurements taken **before the point of equivalence** is reached <br>- <mark class="red">18 hours</mark> of incubation<br><br>Interpretation: <mark class="red">d = log of Ag concentration</mark>::<mark class="red">Fahey-McKelvey/Kinetic</mark> Method
- Uses a <mark class="red">flat surface</mark> – **Petri Dish** or **slide** for precipitation reaction<br>- Both **Ag and Ab DIFFUSE INDEPENDENTLY** in agar gel<br>- (+) Result: <mark class="red">Distinct pattern of precipitation</mark><br><br>- Ab – placed on CENTER well<br>- Ag – placed on SURROUNDING wells<br>::<mark class="red">DOUBLE Diffusion in TWO Dimensions</mark><br><br>aka: <mark class="red">Ouchterlony Technique</mark>
<mark class="red">IDENTICAL</mark><br>![[Pasted image 20240505165516.png]]<br><br><mark class="red">NONIdentical</mark><br>![[Pasted image 20240505165534.png]]<br><br><mark class="red">Partially</mark> Identical<br>![[Pasted image 20240505165547.png]]::Patterns of Precipitation<br><br>spur points to the SIMPLER antigen


### Precipitation by ELECTROPHORETIC TECHNIQUES
?
> [!NOTE]
> usually used when there is MONOCLONAL GAMMOPATHY pattern

![[Pasted image 20240505170041.png]]::<mark class="red">IMMUNOelectrophoresis</mark>
![[Pasted image 20240505170049.png]]::<mark class="red">IMMUNOFIXATION</mark> Electrophoresis


- Protein electrophoresis + immuno<mark class="red">diffusion</mark><br>  - **Antigen**: usually from the patient <mark class="red">SERUM</mark><br>  - **Antibody**: placed on trough cut parallel to separated proteins<br>- Gel is incubated for **18 to 24 hours**<br>- Abnormal contour of precipitin arc may indicate **MONOCLONAL GAMMOPATHY**<br><br>NOT COMMONLY PERFORMED::<mark class="red">IMMUNOelectrophoresis</mark>
- Protein electrophoresis + immuno<mark class="red">precipitation</mark><br>- Specimen is electrophoresed <mark class="red">at 6 positions</mark>, after monospecific antisera is applied directly to the gel’s surface<br>  - **<mark class="red">gamma</mark>, <mark class="red">alpha</mark>, <mark class="red">mu</mark> (heavy chains)**<br>  - **<mark class="red">kappa</mark>, <mark class="red">lambda</mark> (light chains)**<br>- Ag-Ab complexes form, washed and STAIN to visualize.<br>- Used to identify HEAVY and LIGHT chains involved in monoclonal gammopathies::<mark class="red">IMMUNOFIXATION</mark> Electrophoresis

## AGGLUTINATION REACTIONS
?
There are two phases for agglutination reaction: (<mark class="red">IgM</mark>)
1. <mark class="red">Sensitization</mark>: initial reaction which involves Ag-Ab combination through single antigenic determinants on the particle surface. This initial reaction follows the **law of mass action** and is rapid and reversible
2. <mark class="red">Lattice formation</mark>: formation of **cross-links** that form the **visible aggregates**; represents the **stabilization of Ag-Ab complexes** with the binding together of multiple antigenic determinants

### TYPES OF AGGLUTINATION

- AntiGENS are found NATURALLY on a particle<br><br>ABO typing, Widal's test::<mark class="red">Direct</mark> Agglutination
- Employs **PARTICLES (latex, charcoal, bentonite) that are coated** with antiGENS NOT NORMALLY FOUND on their surfaces.<br><br>To detect <mark class="red">Abs</mark>::<mark class="red">Passive/Indirect</mark> Agglutination
- AntiBODIES rather than antigens are attached to a **carrier particle**<br><br>To detect <mark class="red">Ags</mark>::<mark class="red">Reverse Passive</mark> Agglutination
- Uses bacterial protein as inert particles to which **antiBODIES are attached**<br><br><mark class="red">Protein A</mark> (S. aureus) - naturally **binds to the Fc portion of IgG**; complement no longer activated because replaced by Protein A::<mark class="red">Coagglutination</mark>
- Reactions are based on **competition between PARTICULATE and SOLUBLE antigens** for limited antibody-combining sites. LACK OF AGGLUTINATION indicates a POSITIVE reaction.<br><br>Hemagglutination Inhibition (detect Abs to rubella, influenza & RSV)::<mark class="red">Agglutination Inhibition</mark>
- Employs an **antihuman globulin** to detect antibody-coated cells<br><br>aka: **Coomb's test**::<mark class="red">Anti-human globulin-mediated agglutination</mark>


# DISEASES OF THE IMMUNE SYSTEM
## Hypersensitivity
?
- Hypersensitivity is overactivity of the immune system **leading to TISSUE DAMAGE**
- **Coombs and Gel** devised a classification system for 4 types of hypersensitivity
![[IS (ASCPi)#^9mpdbk]]


## Complement Deficiencies

- Primarily manifested by **autoimmune** phenomena such as <mark class="red">LUPUS</mark><br><br>deficient: <mark class="red">C1, C2, C4</mark>::<mark class="red">Classic</mark> pathway deficiency
- Leads to **recurrent** infections with **gram-positive encapsulated** organisms<br>- Most COMMON deficiency: <mark class="red">C2</mark> (also result to **ATHEROSCLEROSIS**)<br>- Most SEVERE deficiency associated with **life-threatening** infections: <mark class="red">C3</mark><br>::<mark class="red">C2 and C3</mark> deficiency
- Symptoms include **recurrent serious systemic** infections, especially <mark class="red">Neisseria meningitidis</mark> and <mark class="red">Neisseria gonorrhea</mark><br><br>C5, 6, 7, 8/ C9 deficiency (NO KNOWN dss)::<mark class="red">Membrane Attack Complex</mark> deficiency
- <mark class="red">Hereditary angioedema (HAE)</mark><br>- **==Urinary histamine== levels and ==serum C1== levels are ELEVATED** during attacks, whereas **==serum CH50, C4, and C2== are DECREASED**. Between attacks, **==C4== is always LOW**, whereas **==C2== levels are NORMAL**<br><br>- First-line therapy is <mark class="red">recombinant C1 inhibitor concentrate</mark>::<mark class="red">C1 esterase inhibitor (C1 INH)</mark> deficiency

[!important]
?
CD55 (DAF) & CD59 (MIRL) deficiency: (+) Paroxysmal Nocturnal Hemoglobinuria

### DIAGNOSIS OF COMPLEMENT ABNORMALITIES
?
![[IS (ASCPi)#^san7kk]]


[!NOTE]
?
**MBL MASP** deficiency: <mark class="red">Pneumococcal dss</mark>
**Factor H & I** deficiency: <mark class="red">Recurrent Pyogenic</mark> infection

## ImmunoDEFICIENCY


- **Arrested differentiation at the ==pre-B cell==** stage leading to **COMPLETE ABSENCE of B cells, plasma cells and immunoglobulins** of all classes.<br>- The underlying genetic mechanism is the **lack of an enzyme called <mark class="red">BTK (Bruton's tyrosine kinase)</mark>**<br><br>affected: B cell::<mark class="red">Bruton's agamma globulinemia/X-linked agammaglobulinemia</mark>
- **Most COMMON congenital** immunodeficiency; usually asymptomatic<br>- Characterized by **lack of <mark class="red">IgA</mark>** with **normal <mark class="red">IgG</mark> and <mark class="red">IgM</mark>**<br><br>affected: B cell::<mark class="red">Selective IgA deficiency</mark>
- Developmental abnormality of the **THIRD and FOURTH pharyngeal pouches** that affects thymus development resulting to a **QUANTItative T cell defect**<br>- **Severely affected neonates** usually present with <mark class="red">tetany</mark> and <mark class="red">cardiac defects</mark><br><br>affected: T cell::<mark class="red">Digeorge anomaly</mark>
- **Rare X-linked recessive** syndrome that is defined by the triad: <mark class="red">thrombocytopenia</mark>, <mark class="red">eczema</mark>, and<mark class="red"> recurrent infections</mark><br>- Abnormalities in **BOTH the cellular and humoral immunity**<br><br>affected: B & T cell::<mark class="red">Wiskott-Aldrich syndrome</mark>
- **Rare autosomal recessive** syndrome characterized by <mark class="red">chronic sinopulmonary disease</mark>, <mark class="red">cerebellar ataxia</mark>, small, dilated blood vessels of the eyes and skin, malignancy, and <mark class="red">progressive neurodegeneration</mark><br><br>affected: B & T cell::<mark class="red">Ataxia Telangiectasia</mark>
- **Most SERIOUS congenital** immunodeficiency<br>- Group of related diseases that affect **T cell and B cell function**<br>- Characterized by severe infections that are **fatal within the first 2 years of life** without treatment<br><br>affected: B & T cell::<mark class="red">Severe Combined Immunodeficiency (SCID)</mark>



## ImmunoPROLIFERATIVE Disorders

- Disorders characterized by **abnormal proliferation of ==CLONAL CELLS==**<br>- Proteins produced: <mark class="red">Intact monoclonal Ig</mark>, <mark class="red">free light and heavy chains</mark><br>- These proteins are referred to as **M protein**, **M band**, **M spike**, **monoclonal spike**, **paraprotein**, **BJP**<br>- Disorders range from **low tumor burden**, **premalignancy**, and **malignancy**<br><br>very important diagnosis: Quantification & ID of the M protein::<mark class="red">Monoclonal Gammopathies</mark>
- Develops in <mark class="red">activated memory B cells</mark> or <mark class="red">plasmablasts</mark><br>- **Chromosomal translocation between the immunoglobulin ==HEAVY chain== and an ==ONCOGENE==** are frequently involved<br>- A single plasma cells clone proliferates producing cytokines that cause localized damage, or antibodies that deposit in various organs::<mark class="red">Multiple Myeloma</mark>
- <mark class="red">Lymphoblastoid cancer</mark><br>- WM cells produce large amounts of <mark class="red">IgM</mark><br>- WM cells reside in the **bone marrow** where they crowd out normal cells<br><br>associated with: **HYPERviscosity syndrome**::<mark class="red">Waldenstrom Macroglobulinema</mark>
- Clonal population of plasma cells producing monoclonal light chain of **kappa** and **lambda** type<br>- Amyloidogenic **light chains misfold**, forming beta pleated sheets<br>- Deposit in tissues in the form of <mark class="red">amyloid fibrils</mark><br>- Interferes with **organ** structure and function::<mark class="red">Light Chain Amyloidosis</mark>
- Affected individuals produce abnormally large numbers of <mark class="red">T and B cells </mark>when infected with **EBV** causing a life-threatening reaction called, “<mark class="red">hemophagocytic lymphohistiocytosis</mark>”<br><br>aka <mark class="red">Duncan dss</mark><br>can also result in **INVERTED CD4:CD8 ratio**<br>**HYPOgammaglobulinemia**::<mark class="red">X-linked Lymphoproliferative Disease</mark>


## Autoimmunity
?
- **Breakdown of self-tolerance** resulting in disease
- Generally most prevalent in **Women of Reproductive age**
- Either **organ specific** or **systemic**
- $ Mechanisms of autoimmunity
	- **Molecular mimicry**
	- **Direct stimulation of autoreactive cells** by foreign antigen
	- **Dysregulation of cytokines**
	- **Increased MHC expression**

[!NOTE] What is assessed?
?
- <mark class="red">Positive selection</mark>
	- ability of the cell to bind an antigen
	- complete TCR
	- IgM
- <mark class="red">Negative selection</mark>
	- recognize self antigen
	- normally T & B cells will NOT bind self antigens
- Apoptosis
	- **90% (B cells)**
	- **97% (T cells)**
- ! Autoimmunity occurs when the cells pass the selection WITHOUT meeting the qualifications

- Affecting **MALES** more than females<br>- Begins in the **sacroiliac joints causing ==VERTEBRAL FUSION==**<br><br>- strongest genetic risk factor: HLA - <mark class="red">B27</mark>::<mark class="red">Ankylosing Spondylitis</mark>
- Antibodies to <mark class="red">adrenal antigens</mark> create **adrenal insufficiency**, leading to hormonal imbalances<br><br>- recognized genetic risk factor: HLA-<mark class="red">DRB1\*04:04</mark>::<mark class="red">Autoimmune Addison Disease</mark>
- Antireceptor antibodies to <mark class="red">TSH receptors</mark><br>- TSI binds to TSH receptors on thyroid follicular cells<br><br>- low TSH, ↑ T4 (Primary HYPERthyroidism)::<mark class="red">Graves Disease</mark>
- T helper cells react to <mark class="red">specific thyroid antigens</mark> and **recruit T cytotoxic cells** that destroy gland tissue<br><br>- ↑ TSH, ↓ T4 (Primary HYPOthyroidism)<br><br>Abs associated: <mark class="red">Anti-microsomal Ab</mark>, <mark class="red">Anti-thyroglobulin</mark>, <mark class="red">Anti-thyroid peroxidase</mark> (TPO) (best choice than the other 2)::<mark class="red">Hashimoto Thyroiditis</mark>
<mark class="red">Type 1</mark> (Classic; 96% cases in US))<br>  - Can occur at **any age**<br>  - HLA-<mark class="red">DRB1\*03</mark> and HLA-<mark class="red">DRB1\*04</mark> are genetic risk factors<br>- <mark class="red">ANA</mark>, <mark class="red">Anti-smooth muscle antibody</mark><br><br><mark class="red">Type 2</mark> (Europe)<br>  - Common in **children** and **young** people<br>  - More SEVERE<br>- anti-LKM1 (anti-liver <mark class="red">kidney microsomal antibody type 1</mark>)<br>- anti-LC1 (anti-liver <mark class="red">cytosol type 1 antibody</mark>)::<mark class="red">Chronic Active Hepatitis</mark>
- Organ-specific disease targeting <mark class="red">biliary epithelial cells</mark><br>- <mark class="red">anti-mitochrondrial Ab</mark> (90% of the cases)::<mark class="red">Primary Biliary Cirrhosis</mark>
- Organ-specific disease targeting the <mark class="red">bile ducts</mark><br>- <mark class="red">ANCA, ANA, ASMA</mark>: common, but NONspecific::<mark class="red">Primary Sclerosing Cholangitis</mark>
- Organ-specific disease that targets the <mark class="red">kidneys</mark> and <mark class="red">lungs</mark><br>- Causes **glomerulonephritis** and **bleeding in the lungs**<br>- <mark class="red">anti-glomerular basement membrane antibody</mark>::<mark class="red">Goodpasture Syndrome</mark>
- <mark class="red">Neuromuscular</mark> disease characterized by **muscle weakness**<br>- <mark class="red">anti-acetylcholine receptor antibodies</mark>::<mark class="red">Myasthenia Gravis</mark>
- Organ-specific disease targeting <mark class="red">parietal cells</mark><br><br>**Type 1**: <mark class="red">anti-intrinsic factor</mark><br>**Type 2**: <mark class="red">anti-parietal cell Ab</mark> (90% cases)<br>::<mark class="red">Pernicious Anemia</mark>
- Systemic disease affecting the <mark class="red">skin</mark>, <mark class="red">subcutaneous tissue</mark>, and <mark class="red">smooth muscle</mark><br>- Characterized by changes in **texture and appearance of the skin**<br>- <mark class="red">ANA, Anti-centromere Ab, Schlederma Ab (Scl-70)</mark>: common::<mark class="red">Progressive systemic sclerosis/ Scleroderma (CREST)</mark>
- Most common form of <mark class="red">CHRONIC inflammatory arthritis</mark><br>- Other manifestations include **interstitial lung disease**, **pleuritis**, **endocarditis**, and **systemic vasculitis**<br>- <mark class="red">Rheumatoid factor</mark> (IgM directed towards the Fc portion of IgG)<br>- INCREASED <mark class="red">CRP</mark> and <mark class="red">ESR</mark> (useful in differentiating from OSTEOARTHRITIS)<br>- **Antinuclear antibody** may also be present<br>- <mark class="red">cyclic citrullinated peptide Ab (anti-CCP)</mark>: 60 - 70% of RF-negative px::<mark class="red">Rheumatoid arthritis</mark>
- Disease that attacks the glands that make <mark class="red">tears</mark> and <mark class="red">saliva</mark>, as well as other body systems including <mark class="red">joints, thyroid, kidneys, liver, lungs, skin, and nerves.</mark><br>- common in women (>40 yo.)<br>- <mark class="red">anti-SSc (Ro), anti-SSb (La)</mark> - frequently positive; **ANA, RF, anti-dsDNA**::<mark class="red">Sjogren syndrome</mark>
- Disease characterized by inflammation of <mark class="red">blood vessels</mark> of the **respiratory tract** and **kidneys**<br><br>Immune-related laboratory testing:<br>  - <mark class="red">CRP</mark> and <mark class="red">ESR</mark><br>  - <mark class="red">ANCA antibodies</mark> are common (NONspecific)<br>  - Reflex positives to<br>    -- <mark class="red">antiproteinase 3 (PR3)</mark> - predominant<br>    -- <mark class="red">myeloperoxidase (MPO)</mark>::<mark class="red">Granulomatosis with polyangiitis (Wegener's granulomatosis)</mark>
- **Systemic rheumatic** disorder<br>- **Impaired ability to clear immune complexes** resulting in tissue injury<br>- <mark class="red">C3</mark> becomes depleted because of autoantibody C3-nephritic factor<br><br>Autoantibodies <br>- <mark class="red">anti-dsDNA</mark> (hallmark)<br>- <mark class="red">anti-Smith (Sm)</mark>: 20% of the cases::<mark class="red">Systemic Lupus Erythematosus</mark>

[!NOTE]
?
if (+) w/ SLE = (+) ANA
a (-) ANA excludes SLE

# TRANSPLANTATION

## Categories of Transplant Donors

Patient receives **own cells or tissue** back::<mark class="red">Autograft</mark>
Patient receives graft from a **family member** or **unrelated individual**::<mark class="red">Allograft/Homograft</mark>
Patient and donor are **identical twins** <mark class="red">Isograft/Syngeneic</mark>
Patient receives a graft from **another species**::<mark class="red">Xenograft/Heterograft</mark>


## Transplant Rejection

- Occurs **within MINUTES to HOURS** after the vascular supply to the transplanted organ is established<br>- Mediated by preformed antibody that **reacts with donor VASCULAR ENDOTHELIUM**<br>- <mark class="red">ABO</mark>, <mark class="red">HLA</mark> and certain <mark class="red">endothelial antigen</mark> may elicit this type of rejection<br><br>- mc cause: ABO incompatibility::<mark class="red">Hyperacute</mark> rejection
- This type of rejection may take place **over SEVERAL DAYS**<br>- Occurs in individuals possessing **VERY LOW LEVELS of preformed donor-specific antibody**::<mark class="red">Accelerated</mark> rejection
- Occurs **DAYS to MONTHS after** transplant<br>- Mediated by a **cellular ALLORESPONSE**, CD4+ T cells produce cytokines and CD8+ T cells mediate cytotoxic reactions<br>- Antibodies produced against HLA antigens bind to vessel walls, **activate complement**, and induce **TRANSMURAL NECROSIS** and **inflammation**::<mark class="red">Acute</mark> rejection
- Remains the **MOST SIGNIFICANT cause of graft loss ==after the first-year==** post-transplant<br>- Results **from a process of GRAFT ARTERIOSCLEROSIS** characterized by <mark class="red">progressive fibrosis and scarring</mark> with **narrowing of vessel lumen** due to proliferation of smooth muscle cells::<mark class="red">Chronic</mark> rejection
- May occur after **100 DAYS post-transplant** or more<br>- T cells in HSC, lung or liver transplants react against foreign HLA proteins in the recipient's cells, causing massive cytokine release, inflammation and tissue destruction in various locations::<mark class="red">Graft vs Host dss</mark>




# TUMOR IMMUNOLOGY

## SELECTED TUMOR MARKERS
?
> [!NOTE]
> significance: check Recurrence of cancer

<mark class="red">AFP</mark>::<mark class="red">**HepatoCELLULAR** carcinoma, **testicular** cancers, **germ cell** carcinoma</mark>
<mark class="red">ALP</mark>::Lung cancer (**Regan isoenzyme**)
<mark class="red">Amylase</mark>::**Pancreatic cancer**
<mark class="red">BJP</mark>::<mark class="red">Multiple myeloma</mark>
<mark class="red">BRCA-1</mark>::**Breast or ovarian cancer**
CA <mark class="red">125</mark>::<mark class="red">Ovarian cancer</mark>
CA <mark class="red">15-3</mark>::<mark class="red">Breast cancer</mark>
CA <mark class="red">19-9</mark>::<mark class="red">**Pancreatic** cancer, **gastric** & **colorectal** cancer</mark>
CA <mark class="red">50</mark>::**Gastric and pancreatic cancers**
CA <mark class="red">27.29</mark>::**Breast cancer (treatment and recurrence)**
<mark class="red">Calcitonin</mark>::<mark class="red">Medullary thyroid carcinoma</mark>
<mark class="red">Cathepsin D</mark>::**Breast cancer**
<mark class="red">CEA</mark>::<mark class="red">Colorectal, stomach, breast, lung cancer</mark>
<mark class="red">CK-1</mark>::**Small cell lung** cancer, **prostate** cancer
<mark class="red">Estrogen receptor</mark>::**Breast cancer**
<mark class="red">GGT</mark>::**Hepatoma**
<mark class="red">HER-2/neu</mark>::**Breast cancer**
<mark class="red">NMP</mark>::<mark class="red">Urinary bladder cancer</mark>
<mark class="red">PSA</mark>::<mark class="red">Prostate</mark>
<mark class="red">CYFRA 21-1</mark>::<mark class="red">**Lung**, **Breast** cancer</mark>

# INFECTIOUS DISEASE

## Syphilis
?
> [!NOTE]
> Treponema pallidum pallidum

### NON-TREPONEMAL TESTS
?
- Used to **<mark class="red">SCREEN</mark> for syphilis** because of their high sensitivity and ease of performance.
- Detects presence of <mark class="red">"reagin" (aka: anti-cardiolipin) antibodies</mark> (non-specific antibodies **directed against cardiolipin constituent of treponemal lipids** but usually derived from its host)
- Tests are based on <mark class="red">flocculation reactions</mark> - patient Ab complexes with the cardiolipin antigen
- Examples:
	- <mark class="red">VDRL (Venereal Disease Research Laboratory)</mark>
	- <mark class="red">RPR (Rapid Plasma Reagin)</mark>
	- <mark class="red">TRUST (Toluidine Red Unheated Serum Test)</mark>
	- <mark class="red">USR (Unheated Serum Reagin)</mark>
	- <mark class="red">RST (Reagin Screen Test)</mark>

- Both a QUALItative and QUANtitative **slide flocculation test** for serum<br>- A modification of the procedure can also apply to **CSF** samples<br><br>Antigen consists of:    <br>- <mark class="red">0.03% cardiolipin    </mark> (**main reacting component**)<br>- <mark class="red">0.9% cholesterol    </mark> (enhances the **reacting surface** of cardiolipin)<br>- <mark class="red">0.21% lecithin</mark> (**removes anticomplementary activity** of cardiolipin)<br><br>Procedure:    <br>- SERUM is heated at **56°C for 30 minutes** to inactivate complement    <br>- Rotation: Serum at <mark class="red">180 rpm for 4 minutes</mark>    <br>- Read **MICROscopically for Flocculation**    <br>- All sera with reactive or weakly reactive results must be tested using the quantitative slide test::<mark class="red">Venereal Disease Research Laboratory (VDRL)</mark>
- The RPR is a **modified VDRL** test involving macroscopic test reaction<br>- The cardiolipin-containing antigen suspension is **bound to CHARCOAL particles**, thus, easier to read.<br>- Mostly used as a screening procedure, **more sensitive but less specific** than VDRL<br><br>Reagent: modified VDRL reagent    <br>- <mark class="red">Cardiolipin, cholesterol, lecithin</mark>    <br>- <mark class="red">Charcoal</mark>: easy visualization of results<br>- <mark class="red">Choline chloride</mark>: inactivate the complement<br>- <mark class="red">EDTA</mark>: prevents lipid oxidation<br>- <mark class="red">Thimerosal</mark>: preservative<br><br>Procedure:    <br>- Specimen: SERUM    <br>- Rotation: <mark class="red">100 rpm for 8 minutes</mark>    <br>- Read **MACROscopically for Flocculation**::<mark class="red">Rapid Plasma Reagin (RPR)</mark>


### TREPONEMAL TESTS
?
- Detect antibody directed **against the T. pallidum organism** or **against specific treponemal Ag.**
- Typically, these tests are **more difficult** to perform and are **more time-consuming**
- Usually utilized as **<mark class="red">CONFIRMATORY</mark> tests**
> [!important] Examples
> - <mark class="red">TPI (Treponema pallidum Immobilization test)</mark>
> - <mark class="red">FTA-ABS (Fluorescent Treponemal Antibody-Absorption test)</mark>
> - <mark class="red">HATTS (Hemagglutination Treponemal Test for Syphilis)</mark>
> - <mark class="red">TPHA (Treponema pallidum Hemagglutination Assay)</mark>
> - <mark class="red">MHA-TP (Microhemagglutination Assay for Antibodies to Treponema pallidum)</mark>

- STANDARD treponemal test (most reliable): **GOLD STANDARD**<br>- Involves mixing of the patient’s serum with live, actively motile T. pallidum extracted **from the testicular chancre of a RABBIT**<br>- Test is (+) if <mark class="red">at least 50% of treponemes are immobilized</mark> (by using **dark-field microscopy**)::<mark class="red">Treponema pallidum Immobilization Test (TPI)</mark>
- Principle: <mark class="red">Indirect Immunoflorescence</mark><br>- Highly sensitive and specific, but it is **time-consuming** to perform.<br><br>Procedure:    <br>- Patient SERUM is heated at **56°C for 30 mins**    <br>- Pre-incubation with NON-pathogenic treponemes, <mark class="red">Reiter's strain</mark> acts as a **“SORBENT” to remove cross-reactivity with other non-pathogenic spirochetes**    <br>- Antigen used: <mark class="red">Nichol's strain</mark> (**virulent strain**) (if px has Ab against Nichol's strain, it won't be absorbed and remain in the sample when washed)    <br>- <mark class="red">Antigen fixed into slides + Patient serum + FITC labeled AHG = **(+) Fluorescence**    </mark><br>- Slides are read under a fluorescence microscope; the intensity of **green color is graded as 0 to 4**.    <br>- No fluorescence indicates a negative test, and a result of <mark class="red">2 or above is considered reactive</mark>.::<mark class="red">Fluorescent Treponemal Antibody-Absorption test (FTA-ABS)</mark>
- Antigen: <mark class="red">RBCs sensitized with **Nichol’s strain**</mark><br>- Uses **glutaraldehyde-stabilized TURKEY red cells** sensitized **with Nichol’s strain** = <mark class="red">HATTS</mark> and <mark class="red">TPHA</mark><br>- Uses **formalinized-SHEEP RBCs** sensitized with Nichol’s strain = <mark class="red">MHA-TP</mark><br>- Presence of T. pallidum antibodies is indicated by **agglutination of the sensitized gel particles**, which form a lattice-like structure that spreads to produce a **smooth mat that covers the well’s surface.**::<mark class="red">Hemagglutination Tests (HATTS, TPHA, MHA-TP)</mark>


### INTERPRETATION OF SYPHILIS TEST RESULTS


RPR reactive; FTA-ABS reactive::Positive for <mark class="red">syphilis</mark>
RPR reactive; FTA-ABS NONreactive::<mark class="red">Biologic F positive</mark> (SLE, RA, IM, pregnancy, elderlies)
RPR NONreactive; FTA-ABS reactive::<mark class="red">Late, Latent or Past infection</mark>

[!NOTE]
?
<mark class="red">VDRL</mark> (test of choice for **REINFECTION**; NOT FTA-ABS because you HAD the infection already = antibody circulating); (test of choice for **CSF (Neurosyphilis)**)

[!NOTE] Case: RPR from a CSF of px w/ (+) titer before. RPR neg. 
?
DON'T perform RPR on CSF, only VDRL. Could be if there is no blood contamination?
DON'T perform heat activation in CSF (no significant amounts of complement)

## Lyme Disease
?
- [[Borrelia burgdorferi]]
- Diagnosis follows a two-tiered approach:
	- SCREENING test: <mark class="red">Enzyme immunoassay, Immunofluorescence assay</mark>
		- if (-) initial, px not NEG yet. consider ALTERNATIVE diagnosis. if SnS consistent w/ LD, consider CONVALESCENT serum.
	- CONFIRMATORY test: <mark class="red">Western blot</mark> (**<=30 days (IgG, IgM)**; **>30 days (IgG)**)
- <mark class="red">Western blot</mark> confirmation of **IgM** antibody presence includes reactivity for **<mark class="red">two</mark> of the three** following bands:
	- <mark class="red">24</mark>, <mark class="red">39</mark> and <mark class="red">41</mark> kDa.
- Confirmation of **IgG** antibody presence is acceptable when **<mark class="red">five</mark> of the scored bands** are present:
	- <mark class="red">18</mark>, <mark class="red">21</mark>, <mark class="red">28</mark>, <mark class="red">30</mark>, <mark class="red">39</mark>, <mark class="red">41</mark>, <mark class="red">45</mark>, <mark class="red">58</mark>, <mark class="red">66</mark> and <mark class="red">93</mark> kDa.
- If serology is NEGATIVE, and SYMPTOMS ARE CONSISTENT with Lyme disease, a <mark class="red">CONVALESCENT serum</mark> should be obtained and tested.

## Group A Streptococcal Infection
?
> [!NOTE] [[S. pyogenes]]

### Anti-Streptolysin O
?
- detect antibodies to the **streptolysin O enzyme**
- To detect the **titer value** in quantitative measurements of positive results, one has to perform <mark class="red">serial dilution</mark> techniques.
- ~ NV: ASO level is usually <mark class="red">less than 160 Todd units</mark> (if HAD streptococcal infection: >=240 Todd units, adult; >=320 Todd units, children)
- Methods:
	- <mark class="red">Latex</mark> – **Passive agglutination**
	- <mark class="red">Hemolytic test</mark> – based on **NEUTRALIZATION** principle of patient antibody
		- look for tube w/ the HIGHEST DILUTION showing NO HEMOLYSIS

[!NOTE]
?
<mark class="red">Anti-DNAse B Testing</mark> (performed on ASO-negative px presenting considerable evidence of Streptococcal infection)

## Infectious Mononucleosis

### CHARACTERISTIC DIAGNOSTIC PROFILE OF EBV

If the patient is SERONEGATIVE; **lacks antibody to VCA**::<mark class="red">Susceptibility</mark>
**Antibody (IgM) to VCA is PRESENT**; EBNA is absent <br> High or rising titer of antibody (**IgG**) to VCA and **no evidence of antibody to EBNA ==after at least 4 weeks== of symptoms**::<mark class="red">Primary infection</mark>
If antibody to **EBNA** and **INCREASED antibodies to EA** are present, patient may be experiencing reactivation<br><br>anti-EBNA - present only in convalescence::<mark class="red">Reactivation</mark>
Antibodies to **VCA and EBNA are PRESENT**::<mark class="red">Past Infection</mark>

### EBV ANTIGEN-SPECIFIC SEROLOGIC TESTS

appears at onset of symptoms, **disappears in 3 months**::anti-<mark class="red">VCA IgM</mark>
appears at onset of symptoms, persists **for life**::anti-<mark class="red">VCA IgG</mark>
also seen **during ACUTE phase**::anti-<mark class="red">EA</mark>
present during **CONVALESCENCE**::anti-<mark class="red">EBNA</mark>

### Serologic Responses of Patients With EBV-ASSOCIATED DISEASE
?
![[IS (ASCPi)#^c5gdb2]]

## Hepatitis A (Infectious Hepatitis)

**Shed in the FECES** of infected individuals during **EARLY ACUTE stage of infection**::<mark class="red">HAV Ag</mark>
Marker of <mark class="red">Acute Hepatitis A</mark> (peaks during the **1st month** of illness)::<mark class="red">IgM</mark> Anti-HAV
It is produced as a result of <mark class="red">natural infection or immunization</mark>::<mark class="red">IgG</mark> Anti-HAV


[!NOTE] Title
?
Shortly **AFTER the onset of FECAL SHEDDING**, an **IgM antibody** is detectable in SERUM, followed within a few days by the appearance of an **IgG antibody**. 
```mermaid
graph LR
A(Stool HAV) --> B(IgM anti-HAV) --> C(IgG anti-HAV) 
``` 


## Hepatitis B (Serum Hepatitis)

### MARKERS OF HBV INFECTION

**Active** hepatitis B infection::<mark class="red">HBs</mark> Ag
**Active** hepatitis B virus infection with **high degree of INFECTIVITY** (marker of infectivity)::<mark class="red">HBe</mark> Ag
**Current or recent acute** hepatitis B; **SOLE MARKER of ACUTE HBV infection** (only (+) marker during the WINDOW period)::<mark class="red">IgM</mark> anti-HBc
Persist for the individual’s **LIFETIME**; indicated **past** infection::<mark class="red">IgG</mark> anti-HBc
**Current or past** hepatitis B<br><br>(IgM HBc + IgG HBc)::<mark class="red">Total anti-HBc</mark>
**Recovery** from hepatitis B::Anti-<mark class="red">HBe</mark>
**Immunity** to hepatitis B::Anti-<mark class="red">HBs</mark>
**Acute, atypical, or OCCULT hepatitis B** <br> <mark class="red">Viral load</mark> may be used to **monitor effectiveness of THERAPY**::<mark class="red">HBV DNA</mark>

### INTERPRETATION OF HEPATITIS B PANEL

HBsAg negative, Anti-HBc negative, Anti-HBs negative::**Susceptible**
HBsAg negative, Anti-HBc POSITIVE, Anti-HBs POSITIVE::Immune due to **infection**
HBsAg negative, Anti-HBc negative, Anti-HBs POSITIVE::Immune due to **vaccination**
HBsAg POSITIVE, Anti-HBc POSITIVE, IgM anti-HBc negative, Anti-HBs negative::**Chronic active infection**<br><br>No anti-HBs produced if HBsAg present
HBsAg negative, Anti-HBc POSITIVE, Anti-HBs negative::Four interpretations possible:    <br>1. Might be **recovering from acute HBV infection**    <br>2. Might be **distantly immune** and test not sensitive enough to detect very low level of anti-HBs in serum    <br>3. **Might be susceptible** with a **false-positive anti-HBc**    <br>4. Might be **undetectable level of HBsAg** present in the serum and the person is **actually chronically infected**

## Human Immunodeficiency Virus Infection
?
- ! The primary target cells of HIV are <mark class="red">CD4+ T lymphocytes and macrophages</mark>.
- **CD4 molecule acts as a RECEPTOR** for attachment of the virus by **binding to the <mark class="red">gp120 envelope protein</mark>**
- <mark class="red">CXCR4</mark> and <mark class="red">CCR5</mark> mediates **ENTRY of the virus** into the host' cells.

### STRUCTURAL GENES OF HIV


codes for <mark class="red">p55</mark>, a precursor **from which four core structural proteins are formed**:<br>    - <mark class="red">p24, p6, p9</mark>: contained in the capsid<br>    - <mark class="red">p17</mark>: found in the layer between the protein core and envelope (matrix)::<mark class="red">gag</mark>
codes for glycoproteins <mark class="red">gp160</mark>, <mark class="red">gp120</mark>, and <mark class="red">gp41</mark>:<br>    - <mark class="red">gp160</mark>: **precursor** protein cleaved to form gp120 and gp41<br>    - <mark class="red">gp120</mark>: forms the **numerous knobs or spikes** that protrude from the outer envelope<br>    - <mark class="red">gp41</mark>: transmembrane glycoprotein that **spans the inner and outer membrane**::<mark class="red">env</mark>
codes for <mark class="red">enzymes</mark> necessary for HIV replication:<br>    - <mark class="red">reverse transcriptase (p51)</mark>: **transcribes** RNA to DNA<br>    - <mark class="red">ribonuclease (p66)</mark>: **degrades original HIV RNA**<br>    - <mark class="red">integrase (p31)</mark>: **inserts viral DNA** into the host’s DNA<br>    - <mark class="red">protease (p10)</mark>**: cleaves precursor protei**ns into active units::<mark class="red">pol</mark>


### HIV INFECTION

- There are **HIGH levels of virus (viremia)**<br>- Flu-like symptoms, fever, lymphadenopathy, sore throat, arthralgia, myalgia, fatigue, rash, weight loss (<mark class="red">ACUTE RETROVIRAL syndrome</mark>: 50 - 70% cases)<br>- Symptoms usually appear **3-6 weeks after** infection (**resolves w/in 7 days**)::<mark class="red">Primary infection</mark>
- There is a **DECREASE in viremia**<br>- However, the virus is still present in the plasma at lower levels<br>- **ABSENCE of clinical symptoms** (length of latency varies) - median length of <mark class="red">10 years</mark><br><br>- <mark class="red">"Window period"</mark><br>- px is **seroACTIVE**::<mark class="red">Clinical Latency</mark>
- There is **profound immunosuppression**<br>- Appearance of **life-threatening infections**<br>- <mark class="red">Absolute CD4+ cell count **less than 200/µl**</mark>::<mark class="red">AIDS</mark>

### APPEARANCE OF HIV MARKERS

**Detectable WITHIN DAYS** of infection::<mark class="red">Viral RNA</mark>
**Core coat** for nucleic acids. <br> Detectable in <mark class="red">2 to 3 weeks</mark>. <br> Becomes **UNDETECTABLE as antibodies develop**, then **detectable again in late stages** as immune system fails and virus replicates::<mark class="red">p24 antigen</mark>
Usually detectable in <mark class="red">2 to 8 weeks</mark>. <br> Transient, **peaks in about 1 to 2 weeks**, undetectable about 1 to 2 weeks later::<mark class="red">IgM antibodies</mark>
Detectable <mark class="red">shortly after IgM</mark>. <br> Long lasting, **gradual increase** in titer over several months.::<mark class="red">IgG antibodies</mark>

### HIV SCREENING AND DIAGNOSIS

#### 1. HIV Antibody Detection

Screening Tests::- <mark class="red">ELISA</mark> (**standard** screening test)<br>- <mark class="red">Microfiltration enzyme immunoassay</mark><br>- <mark class="red">Agglutination tests</mark> (uses **latex, gelatin, or microbead particles**)
Confirmatory Tests::- <mark class="red">WESTERN BLOT</mark> (**standard** confirmatory test for HIV antibody)<br>- <mark class="red">Immunofluorescence assay</mark><br>- <mark class="red">Radioimmunoprecipitation</mark>


[!important] WESTERN BLOT
?
- Prepared **commercially** as <mark class="red">nitrocellulose</mark> or <mark class="red">nylon strips</mark> containing individual HIV proteins
- Any HIV antibodies present will bind to their corresponding antigen on the test membrane
- A result should be reported as POSITIVE if <mark class="red">at least 2 OUT 3 BANDS</mark> are present
	- gp **120/160**
	- gp **41**
	- p **24**
	- p **31**
- To be considered NEGATIVE, NO BANDS
- if 1/4 bands, INDETERMINATE (repeat testing on a later date)
![[Pasted image 20240507104727.png]]


#### 2. QUALItative Nucleic Acid Tests
?
- Used to determine whether or not a detectable level of **HIV NUCLEIC ACID is present in human PLASMA**
- Can be used to **screen or make an<mark class="red"> Initial Diagnosis</mark>,** particularly beneficial in cases where **serological results are inconclusive**.

[!NOTE]
?
to diagnose infants <18 mos.: <mark class="red">Qualitative HIV-1 DNA PCR Test</mark>

## HIV DISEASE MONITORING
?
1. **CD4+ T cell Enumeration** (AIDS: <200 cells/uL, Inverted ratio: 0.5 - 1.0)
	- Normal: <mark class="red">500-1300 cells /μL</mark>
	- Ratio of CD4 to CD8 should be <mark class="red">2:1</mark>
	- The gold standard for enumerating CD4 T cells: <mark class="red">Immunophenotyping with flow cytometry</mark>
2. **Quantitative Viral Load Assays** (depends on sensitivity of method used)
	1. **PCR** (P: target amplification)
	2. **Branched chain DNA assay** (P: signal amplification)
3. **Drug-Resistance Testing**
	1. Genotype test (detect mutation)
	2. Phenotype test (check ability of isolates to grow in the presence of ARV)


# SEROLOGIC AND MOLECULAR PROCEDURES

[!NOTE] Formats of Immunoassay
?
- $ Direct vs Indirect (depends on where label is found)
	- Direct (label/tag is found on the original or primary antibody)
	- Indirect (label/tag is found on the AHG; used to detect Ab)
- $ Competitive vs NONCompetitive
	- Competitive (signal is INVERSELY proportional to the analyte; beyond cut off point = NONREACTIVE)
	- NONCompetitive (signal is DIRECTLY proportional to the analyte; reach cut off point = REACTIVE)
- $ Homogenous vs Heterogenous
	- HOMOgenous (NO separation step)
	- HETEROgenous (w/ separation step: washing; more sensitive)
- #mcl/list-grid 

[!important]
?
- <mark class="red">Radioimmunoassay </mark>
	- labels
		- 3H (Tritiated hydrogen)
		- 125I (Iodine): label of choice
	- M: radioactivity (using <mark class="red">Gamma Scintillation Counter</mark>)
- <mark class="red">Competitive</mark> RIA
	- <mark class="red">RIST (RadioImmunosorbent Assay)</mark>: measure **total IgE**
	- <mark class="red">RAST (RadioAllgergosorbent Assay)</mark>: measure **allergen-specific IgE**
- <mark class="red">Fluorescent</mark> IA
	- fluorescein and rhodamine isothiocyanates
	- M: Fluorescent microscope
- <mark class="red">Enzyme</mark> IA
	- horseradish peroxidase
	- beta galactosidase (from LF)
	- alkaline phosphatase
	- M: Spectrophotometer
- #mcl/list-grid 

## Labelled Immunoassays (EIA/ELISA)
?
- Enzyme immunoassays used **labeled ANTIBODIES** to increase sensitivity
- The CONSTANT REGION of the antibody is **covalently bound with an ENZYME or FLUOROPHORE** that allows the antigen or antibody in the test to be visualized and/or quantified.
> [!NOTE] Title
> ![[Pasted image 20240507105456.png]]


- Antigen is immobilized on the surface and detected with a labeled antibody::<mark class="red">Direct </mark>ELISA
- Antigen is immobilized on the surface<br>- Primary antibody within <mark class="red">patient serum</mark> binds to antigen<br>- Secondary <mark class="red">antihuman-labelled antibody</mark> detects patient antibody to antigen::<mark class="red">Indirect </mark>ELISA
- Uses 2 antibodies that **bind to different places** on the target antigen<br>- <mark class="red">Capture antibody</mark> is immobilized on the surface<br>- Antigen is added<br>- <mark class="red">Labeled detection antibody</mark> is applied in the last step<br><br>- different epitope::<mark class="red">Sandwich</mark> ELISA
- Measures the concentration of an antigen by detection of <mark class="red">signal interference</mark><br>- Antigen is immobilized on the surface<br>- **Sample antigen competes with a REFERENCE ANTIGEN** for binding to a specific amount of labeled antibody<br>- Either ANTIBODY or ANTIGEN may be labeled::<mark class="red">Competitive</mark> ELISA


## Flow Cytometry
?
- <mark class="red">Cell-associated proteins (CD (Clusters of Designation) markers)</mark> are **fluorescently labelled with MONOCLONAL antibodies** to identify cells of interest.
- <mark class="red">Cells suspended in solution</mark> are individually **analyzed for LIGHT SCATTERING PROPERTIES** and the presence of **fluorescently labelled Intracellular or Cell Surface Molecules**


[!NOTE] Applications
?
- Immunophenotyping for **cancer** characterization and **immunodeficiency**
- **DNA ploidy** status
- **CD34** cell enumeration
- Functional assays such as **oxidative burst analysis**
- Characterization of **leukemias** and **lymphomas**
- **Transplantation crossmatch**
- Antibody detection by <mark class="red">BEAD ARRAY</mark>, in which **LABELED BEADS are used in place of cells** and incubated with patient serum


### Instrumentation
?
- Instrument <mark class="red">fluidics</mark> draws cell suspension into sheath fluid, allowing **cells to pass through laser 1 at a time**
- The light source is typically <mark class="red">solid-state diode laser(s)</mark>. The use of **multiple lasers expands the number of fluorochromes** that can be used in the assay
- **LIGHT SCATTER** is detected by <mark class="red">photodiodes</mark>
- **FLUORESCENCE** is detected by <mark class="red">photomultiplier tubes</mark>, creating an **electrical current that is converted into ==voltage pulse== and then to a ==digital signal==**
- **Intensity of signal** is measured on relative scale, typically <mark class="red">1-256 channels</mark>

### Data Acquisition
?
- Cells pass by the <mark class="red">laser</mark> and<mark class="red"> detection system</mark> **1 cell at a time** and the following data are collected:
	- <mark class="red">Forward light scatter</mark> (cell size; bigger the cell, bigger voltage)
	- <mark class="red">Side scatter</mark> (internal granularity/complexity)
	- <mark class="red">Fluorescence</mark> (evaluate extrinsic parameters: antigenic property (eg. detect CD4 by using Ab CD4))
- **GATED data** may be represented as a <mark class="red">single parameter histogram</mark>, <mark class="red">dual-parameter dot plot</mark>, or <mark class="red">quadrant analysis.</mark>



![[Pasted image 20240507114100.png]]::Dual parameter Dot Plot
![[Pasted image 20240507114117.png]]::Single Parameter histogram
![[Pasted image 20240507114127.png]]::https://youtu.be/uWB7IYIBOQQ?t=1871k


[!NOTE] GATING (beta reduction technique: cell population are narrowed down depending on target)
?
![[Pasted image 20240515105243.png]]

### FLOW CYTOMETRY KEY POINTS

Present on **thymocytes**::<mark class="red">CD1</mark>
Coexpression present on **thymocytes**::<mark class="red">CD4+CD8</mark>
CD**2**, CD**3**, CD**5**, CD**7**::Pan <mark class="red">T-Cell</mark>
CD**19**, CD**20**::Pan <mark class="red">B-Cell</mark>
CD**16**, CD**56**, CD**57**::<mark class="red">NK Cells</mark>
CD**13**, CD**14**, CD**33**::<mark class="red">Monocytes</mark>
**kappa** or **lambda**::<mark class="red">Clonality</mark>
**CALLA**::CD<mark class="red">10</mark>
**Stem cell** marker (found in BLAST cells)::CD<mark class="red">34</mark>
Present on all **hematopoietic cells**::CD<mark class="red">45</mark>
<mark class="red">CD19+CD5</mark> with either **kappa** or **lambda**::<mark class="red">CLL Hallmark</mark>


## Fluorescent Antinuclear Antibody Staining
?
- Has been the most widely used and accepted test for ANA detection because it is **highly SENSITIVE** and detects a **wide range of antibodies**
- Principle: <mark class="red">Inverted ELISA/Indirect Fluorescent IA</mark>
- <mark class="red">Epithelial cell/HEp2</mark>: **STANDARD substrate**; have large nuclei with **high antigen expression**, allowing for **high sensitivity** and facilitating visualization of results

[!NOTE]
?
Titer : <mark class="red">>=1:80</mark>

![[Pasted image 20240507114809.png]]::<mark class="red">INDirect ELISA</mark><br><br>- also a HETEROgenous assay: requires washing<br>- Ag NOT specified<br>
![[Pasted image 20240507114823.png]]::<mark class="red">Multiplex IA</mark><br><br>- Advantage: Ag is specified<br>- each bead is coated with a different antigen<br>- each bead incubated w// px serum<br>- px ANA will bind to antigens<br>- fluorescent labelled AHG is added<br>- fluorescent is measured by: **FLOW CYTOMETRY**<br>


### COMMON NUCLEAR PATTERNS AND DISEASE ASSOCIATIONS

- Characterized by **UNIFORM STAINING of the entire nucleus** in interphase cells and condensed chromosomal region in metaphase cells.<br><br>- Typically found in patients with <mark class="red">SLE</mark>, <mark class="red">drug-induced lupus</mark>, and many other autoimmune diseases.<br>- **HIGH titers are SUGGESTIVE of <mark class="red">SLE</mark>**, **LOW titers may be found in <mark class="red">SLE</mark>, <mark class="red">RA</mark>, <mark class="red">Sjogren's syndrome</mark>, and <mark class="red">MCTD</mark>**::<mark class="red">HOMOGENOUS</mark><br><br>mitosis (+)
- **DIFFUSE staining** is seen throughout the nucleus, but there is a **greater staining intensity around the OUTER CIRCLE** surrounding the nucleus in interphase cells. Dividing cells show strong staining of the condensed chromatin.<br><br>- Primarily caused by **antibodies to <mark class="red">dsDNA</mark>** and is **HIGHLY SPECIFIC for <mark class="red">SLE</mark>**<br><br>- entire cell is still HOMOGENOUSLY stained::<mark class="red">PERIPHERAL (rim)</mark><br><br>mitosis (+)
- Characterized by **discrete, fluorescent SPECKS** throughout the nuclei of interphase cells. **Staining is ABSENT in the nucleolus** and in the chromatin region of dividing cells.<br><br>- Associated with **antibodies to <mark class="red">ENAs</mark>** and can be found in patients with <mark class="red">SLE</mark>, <mark class="red">Sjogren's syndrome</mark>, <mark class="red">systemic sclerosis</mark>, and other systemic autoimmune rheumatic diseases::<mark class="red">SPECKLED</mark><br><br>mitosis (-)
- Prominent **smooth, clumpy, or speckled staining of the NUCLEOLI** within the nuclei of interphase cells. The size, shape, and number of nucleoli per cell are variable.<br><br>- Primarily caused by **antibodies to <mark class="red">RNA</mark> and <mark class="red">RNP</mark>** and is seen mainly in patients with <mark class="red">scleroderma</mark>, but can also be present in patients with other <mark class="red">connective tissue diseases</mark>::<mark class="red">NUCLEOLAR</mark><br><br>mitosis (-)
- Numerous, mostly 46, **discrete SPECKLES are seen in the nuclei** of interphase cells and the chromatin of dividing cells.<br><br>- Caused by **antibodies to <mark class="red">proteins in the centromeres</mark> of the chromosomes** and is found mainly in patients with the <mark class="red">CREST syndrome</mark> (Calcinosis, Raynaud's, Esophageal sclerosis, Sclerodactyl, Telangiectasia)::<mark class="red">CENTROMERE</mark><br><br>mitosis (+)

<mark class="red">HOMOGENOUS</mark><br><br>mitosis (+)::anti-<mark class="red">ssDNA</mark>, anti-<mark class="red">dsDNA</mark>, anti-<mark class="red">DNP</mark>, anti-<mark class="red">histone</mark> (drug-induced lupus)
<mark class="red">PERIPHERAL (rim)</mark><br><br>mitosis (+)::anti-<mark class="red">dsDNA</mark>
<mark class="red">SPECKLED</mark><br><br>mitosis (-)::anti-<mark class="red">Sm</mark>, anti-<mark class="red">RNP</mark>, anti-<mark class="red">ENA</mark>, <mark class="red">Ro/SS-A</mark>, <mark class="red">La/SS-B</mark>
<mark class="red">NUCLEOLAR</mark><br><br>mitosis (-)::anti-<mark class="red">RNA polymerase I</mark>, antibodies to <mark class="red">[[IS (ASCPi)#^urux6c\|proteins of small nucleolar RNP complex]]</mark>
<mark class="red">CENTROMERE</mark><br><br>mitosis (+)::anti-<mark class="red">centromere (CENP-A, CENP-B, CENP-C)</mark>, anti-<mark class="red">scl-70</mark>

[!NOTE] Proteins of small nucleolar RNP complex
?
- fibrillin (U3-RNP)
- hU3-55k
- Mpp10
- Th/To
- B23
- PM-Scl
- NOR-90 ^urux6c

[!tip]
?
look for green fluorescence

![[Pasted image 20240507115438.png]]::<mark class="red">Homogenous</mark><br><br>SLE, drug-induced lupus, RA
![[Pasted image 20240507115510.png]]::<mark class="red">Peripheral</mark><br><br>anti-dsDNA, SLE
![[Pasted image 20240507115523.png]]::<mark class="red">Speckled</mark><br><br>SLE, Sjogren's, MCTD, Scleroderma
![[Pasted image 20240507115538.png]]::<mark class="red">Nucleolar</mark><br><br>Scleroderma
![[Pasted image 20240507115550.png]]::<mark class="red">Centromere</mark><br><br>Scleroderma (CREST)<br>number of dots = number of centromere
![[Pasted image 20240507115610.png]]::NOT AN ANA<br><br><mark class="red">Anti-cytoplasmic Ab</mark><br><br>- <mark class="red">antineutrophilic cytoplasmic Ab</mark>,<br>- <mark class="red">islet cell cytoplasmic Ab</mark> (assc.: autoimmune DM),<br>- <mark class="red">liver cytosolic antigen 1 Ab (LC-1)</mark>: Type 2 autoimmune hepatitis

### Anti-dsDNA Quantitation with Crithidia luciliae
?
> [!NOTE]
> For SLE! But can be seen in others, BUT common in SLE.
![[Pasted image 20240507115813.png]]

[!tip]
?
look at <mark class="red">kinetoplast</mark> in staining = (+)
kinetoplast of CL = rich in dsDNA

[!NOTE] Substrates used for ANA pattern
?
- <mark class="red">HEp 2 cell</mark> (standard)
- <mark class="red">Crithidia luciliae</mark> (for anti-dsDNA)
- <mark class="red">mouse kidney cells</mark>

Kinetoplast
?

![[Pasted image 20240507115703.png]]
![[Pasted image 20240507115722.png]]
![[Pasted image 20240507115731.png]]
![[Pasted image 20240507115741.png]]
![[Pasted image 20240507115752.png]]


